Literature DB >> 16928766

Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest.

Matthias Ottinger1, Thomas Christalla, Kavita Nathan, Melanie M Brinkmann, Abel Viejo-Borbolla, Thomas F Schulz.   

Abstract

The Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen 1 (LANA-1) is required for the replication of episomal viral genomes. Regions in its N-terminal and C-terminal domains mediate the interaction with host cell chromatin. Several cellular nuclear proteins, e.g., BRD2/RING3, histones H2A and H2B, MeCP2, DEK, and HP1alpha, have been suggested to mediate this interaction. In this work, we identify the double-bromodomain proteins BRD4 and BRD3/ORFX as additional LANA-1 interaction partners. The carboxy-terminal region of the short variant of BRD4 (BRD4S) containing the highly conserved extraterminal domain directly interacts with an element in the LANA-1 carboxy-terminal domain. We show that ectopically expressed BRD4S and BRD2/RING3 delay progression into the S phase of the cell cycle in epithelial and B-cell lines and increase cyclin E promoter activity. LANA-1 partly releases epithelial and B cells from a BRD4S- and BRD2/RING3-induced G1 cell cycle arrest and also promotes S-phase entry in the presence of BRD4S and BRD2/RING3. This is accompanied by a reduction in BRD4S-mediated cyclin E promoter activity. Our data are in keeping with the notion that the direct interaction of KSHV LANA-1 with BRD4 and other BRD proteins could play a role in the G1/S phase-promoting functions of KSHV LANA-1. Further, our data support a model in which the LANA-1 C terminus contributes to a functional attachment to acetylated histones H3 and H4 via BRD4 and BRD2, in addition to the recently demonstrated direct interaction (A. J. Barbera, J. V. Chodaparambil, B. Kelley-Clarke, V. Joukov, J. C. Walter, K. Luger, and K. M. Kaye, Science 311:856-861, 2006) of the LANA-1 N terminus with histones H2A and H2B.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928766      PMCID: PMC1641788          DOI: 10.1128/JVI.00804-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition.

Authors:  A Dey; J Ellenberg; A Farina; A E Coleman; T Maruyama; S Sciortino; J Lippincott-Schwartz; K Ozato
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.

Authors:  W Zhong; H Wang; B Herndier; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene.

Authors:  G M Platt; G R Simpson; S Mittnacht; T F Schulz
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.

Authors:  S J Gao; L Kingsley; D R Hoover; T J Spira; C R Rinaldo; A Saah; J Phair; R Detels; P Parry; Y Chang; P S Moore
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

5.  Regulation of cyclin E transcription by E2Fs and retinoblastoma protein.

Authors:  Y Geng; E N Eaton; M Picón; J M Roberts; A S Lundberg; A Gifford; C Sardet; R A Weinberg
Journal:  Oncogene       Date:  1996-03-21       Impact factor: 9.867

6.  Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif.

Authors:  Lai-Yee Wong; Gerald A Matchett; Angus C Wilson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Bdf1, a yeast chromosomal protein required for sporulation.

Authors:  P Chua; G S Roeder
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

8.  Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.

Authors:  D Whitby; M R Howard; M Tenant-Flowers; N S Brink; A Copas; C Boshoff; T Hatzioannou; F E Suggett; D M Aldam; A S Denton
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

9.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  97 in total

1.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen and angiogenin interact with common host proteins, including annexin A2, which is essential for survival of latently infected cells.

Authors:  Nitika Paudel; Sathish Sadagopan; Sandhya Balasubramanian; Bala Chandran
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

Review 2.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

3.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition.

Authors:  Jiangfang Wang; Emma L Reuschel; Jason M Shackelford; Lauren Jeang; Debra K Shivers; J Alan Diehl; Xiao-Fang Yu; Terri H Finkel
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

Review 5.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

6.  Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.

Authors:  Brandon L Crowe; Ross C Larue; Chunhua Yuan; Sonja Hess; Mamuka Kvaratskhelia; Mark P Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

7.  Brd4-independent transcriptional repression function of the papillomavirus e2 proteins.

Authors:  Michal-Ruth Schweiger; Matthias Ottinger; Jianxin You; Peter M Howley
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

8.  The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters.

Authors:  Matthias Ottinger; Daniel Pliquet; Thomas Christalla; Ronald Frank; James P Stewart; Thomas F Schulz
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

9.  Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration.

Authors:  Saumya Shree Gupta; Tobias Maetzig; Goedele N Maertens; Azar Sharif; Michael Rothe; Magdalena Weidner-Glunde; Melanie Galla; Axel Schambach; Peter Cherepanov; Thomas F Schulz
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

10.  Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4.

Authors:  Yi-Jan Lin; Takashi Umehara; Makoto Inoue; Kohei Saito; Takanori Kigawa; Moon-Kyoo Jang; Keiko Ozato; Shigeyuki Yokoyama; Balasundaram Padmanabhan; Peter Güntert
Journal:  Protein Sci       Date:  2008-09-24       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.